Abstract. Mutations in the KRAS oncogene can mediate resistance to radiation. KRAS mutation–driven tumors have been reported to express cancer stem cell (CSC)-like features and may harbor metabolic ...

Findings from a phase I/II trial provide clinical proof-of-concept for a first-in-class mRNA-encoded T-cell engager targeting CLDN6 and CD3. Produced in vivo, the bispecific was well tolerated and had ...

Abstract. The RAS family of proto-oncogenes are the most frequently mutated genes in cancer, in which mutations in KRAS account for approximately 25% of all human cancers. RAS oncogenes impair the ...

Abstract. Addition of ENZ or AAP to androgen deprivation therapy (ADT) as first-line treatment for advanced prostate cancer improves survival compared to ADT alone. Genomic alterations in AR associate ...

Summary:. Though NK cells often infiltrate the breast tumor microenvironment, they are frequently described as dysfunctional in this setting, and mechanisms limiting their antitumor cytotoxic ...

Abstract. Purpose: Cancer-associated fibroblasts (CAFs) are highly heterogeneous in pancreatic ductal adenocarcinoma (PDAC). We previously reported that CAFs can acquire an endothelial phenotype under ...

The FDA today approved Bayer’s darolutamide (Nubeqa) for metastatic castration-sensitive prostate cancer (mCSPC) with or without chemotherapy. The decision was based on the results of the phase III ...

Abstract. In this issue of MCT, three articles from the NCI’s Preclinical Chemoradiotherapy Testing Consortium (PCRTC) are presented that each demonstrates a story of success. Each cooperative ...

Drug companies are pouring billions of dollars into PD-1×VEGF bispecific antibodies, hoping these dual-action drugs can outperform existing immunotherapy and anti-angiogenic combinations in lung ...

A 14-gene molecular assay can help identify patients with lung cancer who could benefit from chemotherapy after surgery, according to results of a study presented at the 2025 American Society of ...

We identified men ages 40 to 79 years in the All of Us Research Program who had no history of prostate cancer or elevated PSA at cohort enrollment. PSA distributions were compared across age groups, ...

Results from the phase III ASCENT-04/KEYNOTE-D19 study indicate that the combination of sacituzumab govitecan, a TROP2 antibody–drug conjugate, with the PD-1 inhibitor pembrolizumab is superior to ...